| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 07/13/2000 | WO2000040733A1 Human cyclic nucleotide pdes |
| 07/13/2000 | WO2000040716A2 Soluble receptor br43x2 and methods of using them for therapy |
| 07/13/2000 | WO2000040714A2 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | WO2000040613A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | WO2000040612A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | WO2000040560A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| 07/13/2000 | WO2000040259A1 Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same |
| 07/13/2000 | WO2000040243A1 Novel compounds |
| 07/13/2000 | WO2000040086A1 Formulations for treating disease and methods of using same |
| 07/13/2000 | WO2000025764A3 Compositions for the treatment and prevention of cardiovascular diseases |
| 07/13/2000 | WO2000024741A3 Dihydropyridine compounds and their use as potassium channel openers |
| 07/13/2000 | WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 07/13/2000 | WO2000018801A3 Ncam binding compounds |
| 07/13/2000 | WO2000010958A9 Vitamin d3 mimics |
| 07/13/2000 | CA2753331A1 Soluble receptor br43x2 and methods of using |
| 07/13/2000 | CA2358495A1 Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same |
| 07/13/2000 | CA2358212A1 Formulations for treating disease and methods of using same |
| 07/13/2000 | CA2357950A1 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/12/2000 | EP1018517A2 Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases |
| 07/12/2000 | EP1017836A2 Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
| 07/12/2000 | EP1017815A1 Murine model for human carcinoma |
| 07/12/2000 | EP1017808A2 53bp2 complexes |
| 07/12/2000 | EP1017711A2 Monocyclic compounds with four bifunctional residues having nk-2 antagonist action |
| 07/12/2000 | EP1017672A1 New npy antagonists |
| 07/12/2000 | EP1017667A1 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 07/12/2000 | EP1017664A1 C3a receptor ligands |
| 07/12/2000 | EP1017423A1 Cloning pigs using donor nuclei from differentiated cells |
| 07/12/2000 | EP1017385A1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 |
| 07/12/2000 | EP1017377A2 Use of 6, 7-substituted 2-aminotetralines for the treatment of cytokine mediated inflammatory conditions |
| 07/12/2000 | EP0877734B1 Quinoline and quinazoline compounds useful in therapy |
| 07/12/2000 | EP0680336B1 Monoclonal anti-lfa-1 antibodies for the preparation of a medicament intended to prevent the rejection of organ transplants |
| 07/12/2000 | CN1259944A Treatments of prophylaxis of prostatic cancer and benign prostatic hyperplasia |
| 07/12/2000 | CN1259871A Method of treating chronic progressive vascular scarring diseases |
| 07/12/2000 | CN1054377C New bicyclic derivatives of imidazole and their prepn. process, their use as medicaments and the pharmaceutical compositions containing them |
| 07/12/2000 | CN1054374C New (thia) cycloalkyl [b] indole compounds process for the prepn. thereof and pharmaceutical compositions containing them |
| 07/12/2000 | CN1054373C Full fluoralkyl-substituted bezoylguanidine prepn. pharmaceutical use of same and pharmaceutical containing same |
| 07/12/2000 | CN1054290C Chinese herb medicine prepn. for treating prostate hyperplasia and its preparing method |
| 07/11/2000 | US6087509 Derivatives of trifluorobenzonitriles |
| 07/11/2000 | US6087396 A stable aqueous oxybutynin chloride solution can be placed in an infuser device for treatment of bladder dysfunction |
| 07/11/2000 | US6087381 Pyrazole derivatives as p38 kinase inhibitors |
| 07/11/2000 | US6087360 Method of treating heart failure with endothelin antagonists |
| 07/06/2000 | WO2000039311A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
| 07/06/2000 | WO2000039308A1 Ikk3 kinase |
| 07/06/2000 | WO2000039283A1 Use of cd40 engagement to alter t cell receptor usage |
| 07/06/2000 | WO2000039275A2 Multiple shear stress responsive elements (ssre) and methods of use thereof |
| 07/06/2000 | WO2000039126A1 Method for preparing (r)- (+) -3 {1- [2-( 4-benzoyl- 2-(3,4- difluorophenyl)morpholin- 2-yl)ethyl]- 4-phenylpiperidin -4-yl}-1,1- dimethylurea, its salts solvates and/or hydrates |
| 07/06/2000 | WO2000039120A2 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | WO2000039114A2 Substituted oximes and hydrazones as neurokinin antagonists |
| 07/06/2000 | WO2000039096A1 2-methylimidazoline compounds |
| 07/06/2000 | WO2000039070A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | WO2000038786A2 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038730A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
| 07/06/2000 | WO2000038719A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | WO2000038718A2 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia |
| 07/06/2000 | WO2000038717A2 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 07/06/2000 | WO2000038715A2 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 07/06/2000 | WO2000038684A1 (2-imidazolin-2-ylamino) quinoxaline derivatives for the treatment of pain |
| 07/06/2000 | WO2000038665A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038660A2 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 07/06/2000 | WO2000038653A1 Improved formulation for topical non-invasive application in vivo |
| 07/06/2000 | WO2000018352A3 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/06/2000 | WO2000017222A8 31 human secreted proteins |
| 07/06/2000 | WO2000015770A3 Human serine/threonine protein kinases |
| 07/06/2000 | WO2000014222A3 Gabab receptor subtypes gabab-r1c and gabab-r2 and heterodimers thereof |
| 07/06/2000 | WO2000013703A3 Methods of treating hypertension and compositions for use therein |
| 07/06/2000 | WO1999064035A9 β2-ADRENERGIC RECEPTOR AGONISTS |
| 07/06/2000 | WO1999061600A9 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 07/06/2000 | WO1999054447A3 Human nucleic acid sequences of bladder tumour tissue |
| 07/06/2000 | WO1999052514A3 Pharmaceutical composition and combination preparation for immunosuppressive therapy |
| 07/06/2000 | WO1999046375A3 Human nucleic acid sequences from prostate tissue |
| 07/06/2000 | WO1999046374A3 Human nucleic acid sequences from prostate tumour tissue |
| 07/06/2000 | WO1999041282A8 Therapeutic uses of keratinocyte growth factor-2 |
| 07/06/2000 | CA2358315A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | CA2358094A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
| 07/06/2000 | CA2358067A1 (2-imidazolin-2-ylamino) quinoxaline derivatives for the treatment of pain |
| 07/06/2000 | CA2356986A1 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | CA2356929A1 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356748A1 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356606A1 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356462A1 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356459A1 Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356402A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | CA2356302A1 Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356262A1 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 07/06/2000 | CA2351539A1 Method for preparing (r)- (+) -3 {1- ¬2-( 4-benzoyl- 2-(3,4- difluorophenyl)morpholin- 2-yl)ethyl|- 4-phenylpiperidin -4-yl}-1,1- dimethylurea, its salts solvates and/or hydrates |
| 07/05/2000 | EP1015604A1 Human prl-1 phosphatase |
| 07/05/2000 | EP1015572A2 Nuclear transfer with differentiated fetal and adult donor cells |
| 07/05/2000 | EP1015471A1 Hypoxia-regulated genes |
| 07/05/2000 | EP1015439A1 Prenyl transferase inhibitors |
| 07/05/2000 | EP1015437A1 Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals |
| 07/05/2000 | EP1014984A1 Inhibitors of prenyl-protein transferase |
| 07/05/2000 | EP1014976A1 Novel substituted imidazole compounds |
| 07/05/2000 | EP1014973A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
| 07/05/2000 | EP1014969A1 Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with p-type fimbriae to surfaces |
| 07/05/2000 | EP1014957A1 Urinary incontinence therapy |
| 07/05/2000 | CN1258673A New imidazole derivate and its producing process |
| 07/04/2000 | US6084095 Including 6-amino-4-(3-bromoanilino)pyrido(3,2-d)pyrimidine; 4-(3-bromoanilino)-6-methylaminopyrido (3,2-d)pyrimidine; and 4-(3-bromoanilino)-6-methylaminopyrido(3,2-d)pyrimidine; useful in treating proliferative diseases such as cancer |
| 07/04/2000 | US6083957 Heterocyclic compounds and their preparation and use |
| 07/04/2000 | US6083935 Consisting essentially of an effective amount of n-acetylglucosamine and electrolytes |